Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Elevation Oncology, Inc. (ELEV)
:ELEV
RESEARCH TOOLSreports
Holding ELEV?
Track your performance easily
ELEV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.50 - $5.83
Previous CloseN/A
Volume1.30M
Average Volume (3M)3.08M
Market Cap
$46.14M
Enterprise Value-$36.59M
Total Cash (Recent Filing)$1.74M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding59,119,057
10 Day Avg. Volume7,241,298
30 Day Avg. Volume3,076,943
Standard Deviation0.72
R-Squared0.00758
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.87
Forecast
1Y Price Target
$8.00Price Target Upside1094.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Elevation Oncology News
PremiumCompany Announcements
Elevation Oncology’s Q3 2024 Highlights and Financial Report
Bulls Say, Bears Say
Bulls Say
Clinical Candidate SelectionElevation has announced the selection of EO-1022 as a clinical candidate for development, showing progress in their pipeline expansion.
Combination Therapy Potential92% of mice that received the combination therapy with EO-3021 exhibited a complete response, indicating strong potential efficacy.
Pipeline ProgressElevation Oncology showed progress across the pipeline with additional preclinical data supporting current clinical plans and the nomination of EO-1022.
Bears Say
Clinical PerformanceA stock move of -31% is estimated if the objective response rate (ORR) is less than 30%.
Comparative PerformanceThe 20% ORR in all-comers represents a significant decline from partner CSPC's reported ORR of 47% in all evaluable patients within its Chinese Ph1 trial.
Efficacy ConcernsThe upside scenarios of efficacy in CLDN18.2-low/non-expressors may not materialize, similar to other ADCs.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ELEV FAQ
What was Elevation Oncology, Inc.’s price range in the past 12 months?
Elevation Oncology, Inc. lowest stock price was $0.50 and its highest was $5.83 in the past 12 months.
What is Elevation Oncology, Inc.’s market cap?
Elevation Oncology, Inc.’s market cap is $46.14M.
When is Elevation Oncology, Inc.’s upcoming earnings report date?
Elevation Oncology, Inc.’s upcoming earnings report date is May 01, 2025 which is in 103 days.
How were Elevation Oncology, Inc.’s earnings last quarter?
Elevation Oncology, Inc. released its earnings results on Nov 06, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.19 by -$0.03.
Is Elevation Oncology, Inc. overvalued?
According to Wall Street analysts Elevation Oncology, Inc.’s price is currently Undervalued.
Does Elevation Oncology, Inc. pay dividends?
Elevation Oncology, Inc. does not currently pay dividends.
What is Elevation Oncology, Inc.’s EPS estimate?
Elevation Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elevation Oncology, Inc. have?
Elevation Oncology, Inc. has 59,119,057 shares outstanding.
What happened to Elevation Oncology, Inc.’s price movement after its last earnings report?
Elevation Oncology, Inc. reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.19. Following the earnings report the stock price went down -1.786%.
Which hedge fund is a major shareholder of Elevation Oncology, Inc.?
Among the largest hedge funds holding Elevation Oncology, Inc.’s share is Farallon Capital Management, L.L.C.. It holds Elevation Oncology, Inc.’s shares valued at 2M.
---
Elevation Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (1094.03% Upside)
$8.00 (1094.03% Upside)
Blogger Sentiment
Bullish
ELEV Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.9%
Last 30 Days ▲ 106.7%
Last 30 Days ▲ 106.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.86%
12-Months-Change
Fundamentals
Return on Equity
-63.67%
Trailing 12-Months
Asset Growth
6.33%
Trailing 12-Months
Company Description
Elevation Oncology, Inc.
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
---
ELEV Stock 12 Month Forecast
Average Price Target
$8.00
▲(1094.03% Upside)
Technical Analysis
Immutep
―
Molecular Templates
―
Gritstone bio
―
Adaptimmune Therapeutics
―
Kura Oncology
―
Best Analysts Covering ELEV
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-3.94%
reiterated a buy rating 9 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -3.94% per trade.
---